Zhengye Biotechnology Holding Ltd. has announced several strategic initiatives for 2026 aimed at strengthening its position in the veterinary vaccine sector. The company plans to enhance poultry vaccine sales and expand market share through its newly established subsidiary, Beijing Zhongnong Zhengye Biotechnology Co., Ltd. Additionally, Zhengye has set up a dedicated swine health business unit to integrate sales, technical service, and marketing, with a focus on supporting key accounts and addressing customer needs. The company will also continue to develop commercial relationships with large-scale livestock enterprises and expand technical service capabilities through partnerships with leading research institutions, including the China Agricultural University and Harbin Veterinary Research Institute. Zhengye aims to leverage its recent Nasdaq listing to bolster its capital foundation and support long-term research, development, and commercial growth initiatives.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhengye Biotechnology Holding Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9651883-en) on February 10, 2026, and is solely responsible for the information contained therein.